TACSTD2

MEDSIR presents the results of three new studies at ESMO 2023: LUPER, focusing on lung cancer, and two translational studies of PHERGain in breast cancer

Retrieved on: 
Saturday, October 21, 2023
FDA, SCLC, Metastasis, Gregorio, ESMO, Food, Pembrolizumab, European Society for Medical Oncology, US Foods, American Society of Clinical Oncology, Research, HIV disease progression rates, Carcinoma, Society, Lurbinectedin, Neoplasm, Ecosystem, Cancer, Congress, Breast cancer, Oncology, Immunotherapy, TACSTD2, Patient, Prognosis, ASCO, Medical imaging, Pharmaceutical industry, Medical device

These results showed that approximately one third of patients with early-stage HER2-positive breast cancer could be treated without chemotherapy and remain free of breast cancer for up to three years after surgery.

Key Points: 
  • These results showed that approximately one third of patients with early-stage HER2-positive breast cancer could be treated without chemotherapy and remain free of breast cancer for up to three years after surgery.
  • A total of 28 patients with SCLC who had not previously received immunotherapy were enrolled in the LUPER trial.
  • In the first of the translational studies presented by MEDSIR at ESMO, we analyzed the expression levels of the Trop-2 protein in tumor samples from patients with HER2-positive early breast cancer.
  • The HER2DX® genomic test may prove to be a valuable tool to guide healthcare professionals and patients in personalizing treatment for HER2-positive early breast cancer.

BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023

Retrieved on: 
Monday, October 16, 2023
Congress, Abstract, NSCLC, Regeneron Pharmaceuticals, TACSTD2, Risk, PD-L1, Safety, Entrepreneurship, ESMO, BioNTech, European Society for Medical Oncology, Messenger, ADC, BNTX, Patient, Vaccine, Pharmaceutical industry

Program updates include new data for investigational CAR-T and ex-vivo T cell therapies, a novel ADC, a FixVac off-the-shelf mRNA cancer vaccine, and a bi-specific antibody

Key Points: 
  • Program updates include new data for investigational CAR-T and ex-vivo T cell therapies, a novel ADC, a FixVac off-the-shelf mRNA cancer vaccine, and a bi-specific antibody
    MAINZ, Germany, October 16, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data across its oncology pipeline, covering multiple solid tumor types and novel mechanisms of action, at the European Society for Molecular Oncology (“ESMO”) Congress 2023 in Madrid, Spain from October 20-24, 2023.
  • The initial results show a manageable safety profile and tumor regression in several patients with anti-PD-1 and anti-CTLA4 pretreated advanced or metastatic melanoma.
  • The Company will present first-in-human data of BNT325 (DB-1305) ( NCT05438329 ), a next-generation Trop-2-targeting antibody-drug conjugate (“ADC”), which is being jointly developed with Duality Biologics.
  • In addition, BioNTech will also present pre-clinical data from its BNT314 (GEN1059) program, which is being jointly developed with Genmab.

Peak Bio, Inc. Presents Preclinical Data Highlighting Potential of Differentiated Trop2 PH1 (Novel Payload) ADC in Poster at 2023 AACR Annual Meeting

Retrieved on: 
Wednesday, August 23, 2023
Heart, AACR, Doctor of Pharmacy, Therapy, Preclinical imaging, Peak, PH1, MBA, Antibody, MDR, Immune system, Cancer, OTC, FIC, ADC, DAR, Poster, Spacecraft, POC, TGI, IND, Stomach, TACSTD2, Pharmaceutical industry, Fine chemical

In addition, Peak Bio’s lead payload appears to be a poor substrate for multi-drug resistance (MDR) transporters which is a growing concern in the ADC field.

Key Points: 
  • In addition, Peak Bio’s lead payload appears to be a poor substrate for multi-drug resistance (MDR) transporters which is a growing concern in the ADC field.
  • After some encouraging proof-of-concept (POC) data for Peak Bio’s proprietary ADC approach was presented at AACR 2021, the Company was motivated to explore a pipeline of potentially differentiated ADCs as investigational therapeutics in oncology.
  • Trop2 ADCs, conjugated with PH1 toxin at a drug-to-antibody (DAR) ratio of 4, demonstrated single digit nanomolar potency in eight different solid tumor indications.
  • A proprietary Trop2 PH1 ADC (antibody-linker-toxin), had equal or better on-target potency than first-in-class (FIC) Trop2 ADC.

Xencor Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ICOS, AACR, CD28, European Alliance of Associations for Rheumatology, Cancer, ENPP3, American Association for Cancer Research, Janssen, TACSTD2, NMOSD, Research, CLDN6, Part, Genentech, Antibody, AstraZeneca, CEACAM5, ASCO, Congress, Patient, STEAP1, Ipilimumab, Colorectal cancer, Vir, EULAR, Cytokine, PD-1, Neuromyelitis optica spectrum disorder, Ovarian cancer, European Alliance, IND, Tumor microenvironment, Roche, Vaccine, Pharmaceutical industry, Cryptocurrency, Video game, EU, MorphoSys, Astellas Pharma, Rheumatology, Alexion, Ravulizumab

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.
  • In the first quarter of 2023, Xencor earned $10.5 million of royalty revenue from Alexion on net sales of Ultomiris.
  • Revenues for the first quarter ended March 31, 2023 were $19.0 million, compared to $85.5 million for the same period in 2022.
  • ET (1:30 p.m. PT) to discuss the first quarter 2023 financial results and provide a corporate update.

Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, AACR, Half-life, CD28, CD3, CD86, Cancer, ENPP3, American Association for Cancer Research, TACSTD2, Antibody, CEACAM5, TCR, STEAP1, CD80, Cytokine, Tumor microenvironment, Vaccine

The data were presented in a poster titled “Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors” (Abstract 2983) at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

Key Points: 
  • The data were presented in a poster titled “Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors” (Abstract 2983) at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.
  • T cells in the tumor microenvironment require engagement of both their T cell receptor (TCR) and their co-stimulatory receptors, like CD28, to achieve full activation.
  • Xencor has developed a modular XmAb® bispecific antibody platform that allows for the rapid generation of drug candidates that co-stimulate CD28 only in the presence of tumor cells and TCR engagement.
  • “We are leveraging the plug-and-play nature of our XmAb bispecific antibody platforms to generate and explore additional CD28 drug candidates against a broader universe of solid tumor targets.”

Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023

Retrieved on: 
Tuesday, March 14, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, Tumor microenvironment, AACR, TACSTD2, American Association for Cancer Research, Antibody, Cytokine, Orange County Convention Center, CEACAM5, TCR, STEAP1, CD28, Vaccine

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.
  • “T cells in the tumor microenvironment require engagement of their T cell receptor (TCR) and their co-stimulatory receptors like CD28 to achieve full activation.
  • This is diminished in cancer because tumor cells usually do not express CD28 ligands.
  • We have developed an XmAb antibody platform that allows for the rapid generation of drug candidates that co-stimulate CD28 only in the presence of tumor cells and TCR engagement,” said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor.

Global TROP2 Antibody Market Research Report 2023: Drug Sales & Clinical Trials Outlook 2028 - Approx 20 in Clinical Trials with 2 Expected to be Available in the Market in the Next 5 Years - ResearchAndMarkets.com

Retrieved on: 
Monday, March 13, 2023
Health, Pharmaceutical, Attention, AstraZeneca, Category 1, Breast cancer, Breast, TACSTD2, Indication, Name, Merck, Progression-free survival, Cancer, US FDA, Daiichi Sankyo, Patient, Clinical trial, Therapy, Lung, Neoplasm, Drug development, Science, Lung cancer, III, Vaccine, Pharmaceutical industry, Sacituzumab govitecan, Pembrolizumab

The "Global TROP2 Antibody Market, Drug Sales & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global TROP2 Antibody Market, Drug Sales & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • Even though TROP-2 has garnered curiosity among researchers, there remains just one approved and commercially available antibody against it, Trodelvy.
  • Even though Gilead is leading the current TROP-2 targeted therapy market segment, it is not the only market player.
  • Global TROP2 Antibody Sales Opportunity: > USD 3 Billion
    Approved TROP2 Antibody In Market: 1 Drug (Trodelvy in 2020)
    TROP2 Antibody Clinical Pipeline By Company, Indication & Phase

Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors

Retrieved on: 
Wednesday, March 8, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ADC, Ovarian cancer, Colorectal cancer, Prostate cancer, Cancer, TACSTD, Thyroid cancer, Cell membrane, Neoplasm, Bystander effect, Esophageal cancer, Cervical cancer, DAR, TACSTD2, Glioma, Uterine cancer, Pancreatic cancer, Tissue, Drug discovery, Patient, Lung cancer, Index, Pharmacokinetics, Breast cancer, Stomach, Conference, Spacecraft, Poster, Safety, MTD, Trial of the century, Pharmaceutical industry, Medical imaging, Trophoblast

The multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors aims to evaluate the safety and tolerability of BAT8008.

Key Points: 
  • The multicenter, open-label Phase 1 clinical study in patients with advanced solid tumors aims to evaluate the safety and tolerability of BAT8008.
  • Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with advanced solid tumors.
  • BAT8008 is an antibody-drug conjugate (ADC) targeting Trop2 designed for the treatment of solid tumors.
  • Bio-Thera Solutions is also developing additional ADCs based on its proprietary linker-payload, including ADCs targeting FRα, B7H3, Her2, Nectin-4.

Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories

Retrieved on: 
Tuesday, August 16, 2022
Social conditions in Honduras, Breast cancer, Senior, Chinese, Breast, Nasdaq, PD-1, PD-L1, Good, UC, Goldman Sachs, Immunomedics, Gilead Sciences, Patient, Cell, Company, Infection, HKEX, Partnership, Ropes & Gray, Doctor of Philosophy, TACSTD2, Treatment, Diagnosis, Degenerative disease, News, Agreement, CMC, TNBC, Adult, Terminology, Pharmaceutical industry, Sacituzumab govitecan, Mount Everest, MD

SHANGHAI, Aug. 15, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced that it has entered into an agreement with Immunomedics, Inc., a wholly-owned subsidiary of Gilead Sciences, Inc. (Nasdaq: GILD), whereby Immunomedics will obtain exclusive rights to develop and commercialize Trodelvy® (sacituzumab govitecan) in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia and Mongolia (the "Agreement").

Key Points: 
  • Everest has also submitted applications for commercial approval for Trodelvy in metastatic TNBC with regulatory bodies in South Korea, Taiwan and Hong Kong.
  • We thank Everest Medicines for their partnership and important contributions in the development of Trodelvy in Asia.
  • Their collaboration has brought us closer to bringing Trodelvy to patients who need alternative options," said Bill Grossman, MD, PhD, Senior Vice President, Oncology Clinical Research, Gilead Sciences.
  • Goldman Sachs served as financial advisor to Everest Medicines while Ropes & Gray LLP served as legal counsel to the Company.

OBI Pharma Announces Discontinuation of the Phase 1/2 Study of its Antibody- OBI 888 to focus on other priority Cancer programs

Retrieved on: 
Tuesday, July 5, 2022
Patient, ADC, CEO, GLOBE, Securities and Futures Bureau, AKR1C3, OBI Pharma, Inc., Cancer, OBI, Globo H, TACSTD2, Globo, Private Securities Litigation Reform Act, Risk, Fine chemical, Pharmaceutical industry, Pharma

We are pleased that the preliminary data from our Phase 1/2 study demonstrated that OBI 888 is a safe and well tolerated product and showed some trends of efficacy.

Key Points: 
  • We are pleased that the preliminary data from our Phase 1/2 study demonstrated that OBI 888 is a safe and well tolerated product and showed some trends of efficacy.
  • We have therefore decided to discontinue OBI-888 development and focus on our novel cancer pipeline under Phase 3 (Adagloxad Simolenin-vaccine) and Phase 2 (OBI 999-ADC, OBI 833-vaccine and OBI 3424-small molecule) clinical development.
  • The OBI-888 clinical study report is estimated to be finalized in Q4, 2022 and presented at a future medical conference.
  • OBI Pharma is excited to develop and validate our novel anti-Globo H, AKR1C3 and Trop 2 pipeline to fulfill unmet medical needs of cancer patients, stated, Michael Chang, OBI Pharma Chairman and CEO.